Bedrijfsoverzicht
Neurogene Inc. is a clinical stage biotechnology firm dedicated to developing genetic medicines specifically for rare neurological diseases, focusing on product candidates such as NGN-401 and NGN-101. The company operates within the healthcare sector and the biotechnology industry, positioning itself to address unmet medical needs in specialized therapeutic areas through advanced research and development. As of the latest data, the enterprise holds a market capitalization of $317.40M and employs 131 individuals across its operations. The absence of reported annual revenue in the available facts indicates that the company is currently in a pre-commercialization phase where capital expenditure is primarily directed toward clinical trials rather than sales generation, a typical characteristic for entities at this developmental stage. This specific valuation scale reflects the market's assessment of the company's potential based on its pipeline assets rather than historical financial performance or established cash flows from product sales.
Financiële gezondheid
The financial statements for Neurogene Inc. show a revenue figure that is not available for the trailing twelve months, while the net income stands at a significant loss of $-90,351,000 and EBITDA is reported at $-100,116,000. The substantial gap between the reported revenue (which is effectively zero or negligible given the N/A status) and the deep net loss reveals a cost structure dominated by high burn rates associated with ongoing clinical research and development activities. The company generates negative free cash flow of $-46,465,124, which implies that cash outflows for operations and investing activities exceed cash inflows, a situation requiring significant external financing or existing cash reserves to maintain solvency. All three margin metrics—gross margin, operating margin, and profit margin—are recorded at 0.0%, indicating that the company has not yet achieved profitability or that the standard margin calculations are not applicable due to the lack of commercial revenue. On the balance sheet, the company holds cash of $269.01M against total debt of $9.89M, resulting in a debt-to-equity ratio of 3.73, which suggests a leveraged capital structure relative to equity but highlights a robust cash position relative to obligations. The current ratio is an exceptionally high 16.56, signaling strong short-term liquidity capabilities provided by the cash reserves, although this metric is often skewed in biotech firms with minimal current liabilities. Return on Equity is -31.4% and return on assets is -20.7%, metrics that reveal that management is currently utilizing shareholder capital to generate losses rather than returns, a common feature for early-stage companies investing heavily in growth initiatives.
Waarderingsbeoordeling
The trailing twelve-month P/E ratio is not available, while the forward P/E is listed as -3.68, a negative figure that implies expected earnings are still negative and precludes traditional earnings-based valuation multiples. The price-to-book ratio stands at 1.19, suggesting that the market values the company at a slight premium over its net asset value, potentially reflecting the intrinsic worth of its intellectual property and clinical pipeline. The price-to-sales ratio and EV/EBITDA are not available or are negative at -0.58 respectively, indicating that alternative valuation methods relying on sales or earnings multiples are not applicable or result in negative values due to the company's financial profile. The stock has traded within a 52-week range with a high of $37.27 and a low of $10.28, meaning the current market price sits somewhere within this wide band, reflecting high volatility typical of small-cap biotechnology stocks. The beta value is 1.89, which indicates that the stock's price volatility is significantly higher than the broader market, moving approximately 89% more aggressively than the benchmark index during periods of market fluctuation.
Growth & Income
The revenue growth year-over-year and earnings growth year-over-year are both listed as not available, reflecting the fact that the company has not yet generated consistent commercial sales to calculate meaningful growth rates. Since the company does not pay a dividend, as evidenced by a dividend yield of N/A and a payout ratio of 0.0%, it operates under a strategy where earnings are not distributed to shareholders but are instead retained to fund research and development efforts. Consequently, the company reinvests its limited operational earnings and cash reserves directly into expanding its product pipeline and advancing clinical trials rather than providing income distributions to investors. The overall growth and income profile is characterized by a complete reliance on capital appreciation potential through pipeline progression rather than current income generation or historical earnings growth.